Publications by authors named "Kiyo Nagamori"
Background: Systemic therapy for metastatic clear cell sarcoma (CCS) bearing EWSR1-CREB1/ATF1 fusions remains an unmet clinical need in children, adolescents, and young adults.
Methods: To identify key signaling pathway vulnerabilities in CCS, a multi-pronged approach was taken: (i) genomic and transcriptomic landscape analysis, (ii) integrated chemical biology interrogations, (iii) development of CREB1/ATF1 inhibitors, and (iv) antibody-drug conjugate testing (ADC). The first approach encompassed DNA exome and RNA deep sequencing of the largest human CCS cohort yet reported consisting of 47 patient tumor samples and 8 cell lines.
Article Synopsis
- Metastatic epithelioid sarcoma (EPS) is a serious health issue for kids and young adults, and current treatments like the drug tazemetostat aren't fully effective.
- Scientists studied cancer samples from patients to find weak points in the disease and used advanced technology to help identify potential treatments.
- They discovered that there are important differences between EPS in younger patients and older ones, which suggests that doctors should treat them as separate types of the disease.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and phenocopies a muscle precursor that fails to undergo terminal differentiation. The alveolar subtype (ARMS) has the poorest prognosis and represents the greatest unmet medical need for RMS. Emerging evidence supports the role of epigenetic dysregulation in RMS.
View Article and Find Full Text PDF